Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marina Pedemonte is active.

Publication


Featured researches published by Marina Pedemonte.


Neuromuscular Disorders | 1999

Clinical and genetic heterogeneity in autosomal recessive nemaline myopathy

Carina Wallgren-Pettersson; Katarina Pelin; Pirta Hilpelä; Kati Donner; Berardino Porfirio; Claudio Graziano; Kathryn J. Swoboda; Michel Fardeau; J. Andoni Urtizberea; Francesco Muntoni; C. Sewry; Victor Dubowitz; Susan T. Iannaccone; Carlo Minetti; Marina Pedemonte; Marco Seri; Roberto Cusano; Martin Lammens; Avril Castagna-Sloane; Alan H. Beggs; Nigel G. Laing; Albert de la Chapelle

Autosomal recessive nemaline (rod) myopathy is clinically and genetically heterogeneous. A clinically distinct, typical form, with onset in infancy and a non-progressive or slowly progressive course, has been assigned to a region on chromosome 2q22 harbouring the nebulin gene Mutations have now been found in this gene, confirming its causative role. The gene for slow tropomyosin TPM3 on chromosome 1q21, previously found to cause a dominantly inherited form, has recently been found to be homozygously mutated in one severe consanguineous case. Here we wished to determine the degree of genetic homogeneity or heterogeneity of autosomal recessive nemaline myopathy by linkage analysis of 45 families from 10 countries. Forty-one of the families showed linkage results compatible with linkage to markers in the nebulin region, the highest combined lod scores at zero recombination being 14.13 for the marker D2S2236. We found no indication of genetic heterogeneity for the typical form of nemaline myopathy. In four families with more severe forms of nemaline myopathy, however, linkage to both the nebulin and the TPM3 locus was excluded. Our results indicate that at least three genetic loci exist for autosomal recessive nemaline myopathy. Studies of additional families are needed to localise the as yet unknown causative genes, and to fully elucidate genotype-phenotype correlations.


Neurology | 2006

Expanding the clinical spectrum of POMT1 phenotype

Anna D'amico; Alessandra Tessa; C. Bruno; Stefania Petrini; Roberta Biancheri; Marika Pane; Marina Pedemonte; Enzo Ricci; A. Falace; Andrea Rossi; Eugenio Mercuri; Filippo M. Santorelli; Enrico Bertini

Mutations in POMT1 have been identified in Walker–Warburg syndrome and in patients with limb-girdle muscular dystrophy and mental retardation (LGMD2K). The authors report new POMT1 mutations in three unrelated children with severe motor impairment, leg hypertrophy, and mental retardation but without brain and ocular malformations. These patients are similar to LGMD2K but have earlier onset and more severe motor disability. The current findings expand the spectrum of POMT1-associated phenotypes.


Neurology | 2004

Clinical and molecular findings in patients with giant axonal neuropathy (GAN)

C. Bruno; Enrico Bertini; Antonio Federico; E. Tonoli; Maria Luisa Lispi; Denise Cassandrini; Marina Pedemonte; Filippo M. Santorelli; Mirella Filocamo; Maria Teresa Dotti; Angelo Schenone; Alessandro Malandrini; Carlo Minetti

Giant axonal neuropathy (GAN) is a rare autosomal recessive neurodegenerative disorder of early onset, clinically characterized by a progressive involvement of both peripheral and CNS. The diagnosis is based on the presence of characteristic giant axons, filled with neurofilaments, on nerve biopsy. Recently, the defective protein, gigaxonin, has been identified and different pathogenic mutations in the gigaxonin gene have been reported as the underlying genetic defect. Gigaxonin, a member of the BTB/kelch superfamily proteins, seems to play a crucial role in the cross talk between the intermediate filaments and the membrane network. The authors report clinical and molecular findings in five Italian patients with GAN. This study shows the allelic heterogeneity of GAN and expands the spectrum of mutations in the GAN gene. The frequent occurrence of private mutations stresses the importance of a complete gene analysis.


Neuromuscular Disorders | 2014

Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy

Marika Pane; E. Mazzone; Lavinia Fanelli; Roberto De Sanctis; Flaviana Bianco; Serena Sivo; Adele D’Amico; Sonia Messina; Roberta Battini; Marianna Scutifero; Roberta Petillo; Silvia Frosini; Roberta Scalise; Gianluca Vita; Claudio Bruno; Marina Pedemonte; Tiziana Mongini; Elena Pegoraro; Francesca Brustia; Alice Gardani; Angela Berardinelli; Valentina Lanzillotta; Emanuela Viggiano; Filippo Cavallaro; Maria Sframeli; Luca Bello; Andrea Barp; Serena Bonfiglio; Enrica Rolle; Giulia Colia

The Performance of Upper Limb was specifically designed to assess upper limb function in Duchenne muscular dystrophy. The aim of this study was to assess (1) a cohort of typically developing children from the age of 3years onwards in order to identify the age when the activities assessed in the individual items are consistently achieved, and (2) a cohort of 322 Duchenne children and young adults to establish the range of findings at different ages. We collected normative data for the scale validation on 277 typically developing subjects from 3 to 25years old. A full score was consistently achieved by the age of 5years. In the Duchenne cohort there was early involvement of the proximal muscles and a proximal to distal progressive involvement. The scale was capable of measuring small distal movements, related to activities of daily living, even in the oldest and weakest patients. Our data suggest that the assessment can be reliably used in both ambulant and non ambulant Duchenne patients in a multicentric setting and could therefore be considered as an outcome measure for future trials.


Annals of Neurology | 2007

Phenotypic characterization of hypomyelination and congenital cataract.

Roberta Biancheri; Federico Zara; Claudio Bruno; Andrea Rossi; Laura Bordo; Elisabetta Gazzerro; Federica Sotgia; Marina Pedemonte; Sara Scapolan; Massimo Bado; Graziella Uziel; Marianna Bugiani; Laura Doria Lamba; Valeria Costa; Angelo Schenone; Annemieke Rozemuller; Paolo Tortori-Donati; Michael P. Lisanti; Marjo S. van der Knaap; Carlo Minetti

To define the clinical and laboratory findings in a novel autosomal recessive white matter disorder called hypomyelination and congenital cataract, recently found to be caused by a deficiency of a membrane protein, hyccin, encoded by the DRCTNNB1A gene located on chromosome 7p21.3‐p15.3.


Laboratory Investigation | 2008

Caveolin-3 T78M and T78K missense mutations lead to different phenotypes in vivo and in vitro.

Monica Traverso; Elisabetta Gazzerro; Stefania Assereto; Federica Sotgia; Roberta Biancheri; Silvia Stringara; Laura Giberti; Marina Pedemonte; Xiabo Wang; Sara Scapolan; E. Pasquini; Maria Anna Donati; Federico Zara; Michael P. Lisanti; Claudio Bruno; Carlo Minetti

Caveolins are the principal protein components of caveolae, invaginations of the plasma membrane involved in cell signaling and trafficking. Caveolin-3 (Cav-3) is the muscle-specific isoform of the caveolin family and mutations in the CAV3 gene lead to a large group of neuromuscular disorders. In unrelated patients, we identified two distinct CAV3 mutations involving the same codon 78. Patient 1, affected by dilated cardiomyopathy and limb girdle muscular dystrophy (LGMD)-1C, shows an autosomal recessive mutation converting threonine to methionine (T78M). Patient 2, affected by isolated familiar hyperCKemia, shows an autosomal dominant mutation converting threonine to lysine (T78K). Cav-3 wild type (WT) and Cav-3 mutations were transiently transfected into Cos-7 cells. Cav-3 WT and Cav-3 T78M mutant localized at the plasma membrane, whereas Cav-3 T78K was retained in a perinuclear compartment. Cav-3 T78K expression was decreased by 87% when compared with Cav-3 WT, whereas Cav-3 T78M protein levels were unchanged. To evaluate whether Cav-3 T78K and Cav-3 T78M mutants behaved with a dominant negative pattern, Cos-7 cells were cotransfected with green fluorescent protein (GFP)-Cav-3 WT in combination with either mutant or WT Cav-3. When cotransfected with Cav-3 WT or Cav-3 T78M, GFP-Cav-3 WT was localized at the plasma membrane, as expected. However, when cotransfected with Cav-3 T78K, GFP-Cav-3 WT was retained in a perinuclear compartment, and its protein levels were reduced by 60%, suggesting a dominant negative action. Accordingly, Cav-3 protein levels in muscles from a biopsy of patient 2 (T78K mutation) were reduced by 80%. In conclusion, CAV3 T78M and T78K mutations lead to distinct disorders showing different clinical features and inheritance, and displaying distinct phenotypes in vitro.


Neurogenetics | 2012

TRPV4 mutations in children with congenital distal spinal muscular atrophy

Chiara Fiorillo; Francesca Moro; Giacomo Brisca; Guja Astrea; Claudia Nesti; Zoltán Bálint; Andrea Olschewski; Maria Chiara Meschini; Christian Guelly; Michaela Auer-Grumbach; Roberta Battini; Marina Pedemonte; Alessandro Romano; Valeria Menchise; Roberta Biancheri; Filippo M. Santorelli; Claudio Bruno

Inherited disorders characterized by motor neuron loss and muscle weakness are genetically heterogeneous. The recent identification of mutations in the gene encoding transient receptor potential vanilloid 4 (TRPV4) in distal spinal muscular atrophy (dSMA) prompted us to screen for TRPV4 mutations in a small group of children with compatible phenotype. In a girl with dSMA and vocal cord paralysis, we detected a new variant (p.P97R) localized in the cytosolic N-terminus of the TRPV4 protein, upstream of the ankyrin-repeat domain, where the great majority of disease-associated mutations reside. In another child with congenital dSMA, in this case associated with bone abnormalities, we detected a previously reported mutation (p.R232C). Functional analysis of the novel p.P97R mutation in a heterologous system demonstrated a loss-of-function mechanism. Protein localization studies in muscle, skin, and cultured skin fibroblasts from both patients showed normal protein expression. No TRPV4 mutations were detected in four children with dSMA without bone or vocal cord involvement. Adding to the clinical and molecular heterogeneity of TRPV4-associated diseases, our results suggest that molecular testing of the TRPV4 gene is warranted in cases of congenital dSMA with bone abnormalities and vocal cord paralysis.


Orphanet Journal of Rare Diseases | 2016

MYH7-related myopathies: clinical, histopathological and imaging findings in a cohort of Italian patients.

Chiara Fiorillo; Guja Astrea; Marco Savarese; Denise Cassandrini; Giacomo Brisca; Federica Trucco; Marina Pedemonte; Rosanna Trovato; Lucia Ruggiero; Liliana Vercelli; Adele D'Amico; Giorgio A. Tasca; Marika Pane; Marina Fanin; Luca Bello; Paolo Broda; Olimpia Musumeci; Carmelo Rodolico; Sonia Messina; Gian Luca Vita; Maria Sframeli; Sara Gibertini; Lucia Morandi; Marina Mora; Lorenzo Maggi; Antonio Petrucci; Roberto Massa; Marina Grandis; Antonio Toscano; Elena Pegoraro

BackgroundMyosin heavy chain 7 (MYH7)-related myopathies are emerging as an important group of muscle diseases of childhood and adulthood, with variable clinical and histopathological expression depending on the type and location of the mutation. Mutations in the head and neck domains are a well-established cause of hypertrophic cardiomyopathy whereas mutation in the distal regions have been associated with a range of skeletal myopathies with or without cardiac involvement, including Laing distal myopathy and Myosin storage myopathy. Recently the spectrum of clinical phenotypes associated with mutations in MYH7 has increased, blurring this scheme and adding further phenotypes to the list. A broader disease spectrum could lead to misdiagnosis of different congenital myopathies, neurogenic atrophy and other neuromuscular conditions.ResultsAs a result of a multicenter Italian study we collected clinical, histopathological and imaging data from a population of 21 cases from 15 families, carrying reported or novel mutations in MYH7. Patients displayed a variable phenotype including atypical pictures, as dropped head and bent spine, which cannot be classified in previously described groups. Half of the patients showed congenital or early infantile weakness with predominant distal weakness. Conversely, patients with later onset present prevalent proximal weakness. Seven patients were also affected by cardiomyopathy mostly in the form of non-compacted left ventricle. Muscle biopsy was consistent with minicores myopathy in numerous cases. Muscle MRI was meaningful in delineating a shared pattern of selective involvement of tibialis anterior muscles, with relative sparing of quadriceps.ConclusionThis work adds to the genotype-phenotype correlation of MYH7-relatedmyopathies confirming the complexity of the disorder.


Journal of Child Neurology | 2006

Mitochondrial DNA Deletion in a Child With Mitochondrial Encephalomyopathy, Growth Hormone Deficiency, and Hypoparathyroidism

Denise Cassandrini; Salvatore Savasta; Mauro Bozzola; Alessandra Tessa; Marina Pedemonte; Stefania Assereto; Silvia Stringara; Carlo Minetti; Filippo M. Santorelli; Claudio Bruno

We report an 11-year-old boy with short stature, bilateral ptosis, sensorineural hearing loss, muscle weakness, and endocrine abnormalities. Brain magnetic resonance imaging (MRI) showed a bilateral abnormal signal in the globus pallidus and in the midbrain tegment. Muscle biopsy specimens showed ragged red and cytochrome c oxidase negative fibers, and biochemical analysis of muscle homogenate showed a partial defect of complex I and IV activities of the respiratory chain enzymes. Analysis of mitochondrial DNA by a polymerase chain reaction screening procedure and Southern blot revealed a novel heteroplasmic single mitochondrial DNA deletion of 7.8 kb in different tissues. This deletion was absent in the blood DNA of his mother and brother. This case further expands and confirms the wide clinical spectrum of mitochondrial disorders associated with single large-scale mitochondrial DNA deletions. (J Child Neurol 2006;21:983—985; DOI 10.2310/7010.2006.00218).


PLOS Currents | 2014

The 6 Minute Walk Test and Performance of Upper Limb in Ambulant Duchenne Muscular Dystrophy Boys

Marika Pane; E. Mazzone; Serena Sivo; Lavinia Fanelli; Roberto De Sanctis; Adele D’Amico; Sonia Messina; Roberta Battini; Flaviana Bianco; Marianna Scutifero; Roberta Petillo; Silvia Frosini; Roberta Scalise; Gian Luca Vita; Claudio Bruno; Marina Pedemonte; Tiziana Mongini; Elena Pegoraro; Francesca Brustia; Alice Gardani; Angela Berardinelli; Valentina Lanzillotta; Emanuela Viggiano; Filippo Cavallaro; Maria Sframeli; Luca Bello; Andrea Barp; Fabio Busato; Serena Bonfiglio; Enrica Rolle

The Performance of Upper Limb (PUL) test was specifically developed for the assessment of upper limbs in Duchenne muscular dystrophy (DMD). The first published data have shown that early signs of involvement can also be found in ambulant DMD boys. The aim of this longitudinal Italian multicentric study was to evaluate the correlation between the 6 Minute Walk Test (6MWT) and the PUL in ambulant DMD boys. Both 6MWT and PUL were administered to 164 ambulant DMD boys of age between 5.0 and 16.17 years (mean 8.82). The 6 minute walk distance (6MWD) ranged between 118 and 557 (mean: 376.38, SD: 90.59). The PUL total scores ranged between 52 and 74 (mean: 70.74, SD: 4.66). The correlation between the two measures was 0.499. The scores on the PUL largely reflect the overall impairment observed on the 6MWT but the correlation was not linear. The use of the PUL appeared to be less relevant in the very strong patients with 6MWD above 400 meters, who, with few exceptions had near full scores. In patients with lower 6MWD the severity of upper limb involvement was more variable and could not always be predicted by the 6MWD value or by the use of steroids. Our results confirm that upper limb involvement can already be found in DMD boys even in the ambulant phase.

Collaboration


Dive into the Marina Pedemonte's collaboration.

Top Co-Authors

Avatar

Carlo Minetti

Istituto Giannina Gaslini

View shared research outputs
Top Co-Authors

Avatar

Claudio Bruno

Istituto Giannina Gaslini

View shared research outputs
Top Co-Authors

Avatar

Chiara Fiorillo

Istituto Giannina Gaslini

View shared research outputs
Top Co-Authors

Avatar

Federica Trucco

Istituto Giannina Gaslini

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Federico Zara

Istituto Giannina Gaslini

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marika Pane

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Enrico Bertini

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge